Organization | Korean Breast Cancer Society

Korean Breast Cancer Society Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Seoul Korea, Republic of (1996)

Organization Overview

First Clinical Trial

2007

NCT00912938

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 4 Trials (3)

letrozole (femara) (1 trial)

paclitaxel (taxol) (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 3 Trials (5)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (3 trials)

doxorubicin (Doxil) (1 trial)

goserelin (zoladex) (2 trials)

tamoxifen (nolvadex) (2 trials)

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 10